Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinmajiedu Granules for acute respiratory distress syndrome
ChiCTR2300070227Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Yinmajiedu Granules in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Ventilator-free days. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
Yinmajiedu Granules
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2300070227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070227.